Gynecology Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

Gynecology Drugs Market Analysis

The gynecology drugs market is expected to register a CAGR of 6.2% over the forecast period.

The outbreak of the COVID-19 pandemic has pushed the pharmaceutical industry into action, with a race to develop both therapeutic and preventive drugs. Exponentially increasing cases of the coronavirus worldwide are leading to the need for the development of novel treatments, with several clinical trials underway. The COVID-19 pandemic has considerably impacted the management of patients with gynecologic cancers. Many centers have reduced access to routine visits to avoid crowded waiting areas especially to reduce the infection risk for oncologic patients. Cancer patients were a vulnerable group of patients with a high risk of COVID-19 infection, and infected patients may suffer from more deteriorating conditions and unlikely outcomes. As per the study titled, "Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)" in 2021, the multidisciplinary gynecologic cancer team at the Hospital del Mar reconsidered patterns of surveillance to propose telemedicine-based follow-up strategies for cervical, endometrial, and ovarian cancer patients. In addition, as per the study titled, "Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective" published in January 2022, the management of gynecological cancers has suffered during the pandemic, partly due to lockdown and partly due to directing resources to manage COVID-19 patients. It also stated that modification of gynecological cancer management during the pandemic was recommended. Therefore such instances indicate that the market witnessed slow growth during the pandemic. However, with the ease of restrictions and lockdowns and declining cases of COVID-19, the market is expected to witness considerable growth over the forecast period.

The rising incidence of various gynecological cancer is projected to be continued in the future which is likely to fuel the demand for efficient treatment driving the global gynecological drugs market over the forecast period. According to the data published by the National Cancer Institute in January 2022, the estimated number of new cervical cancer cases in 2022 is around 14,100 in the United States which is around 0.7% up from previous years of all new cancer cases. It also reported that around 4,280 women will die from cervical cancer in 2022. Similarly, as per the report published by the American Cancer Society in January 2022, around 19,880 women are expected to receive a new diagnosis of ovarian cancer and around 12,810 women are expected to die from ovarian cancer in the United States in 2022. Therefore, such a high prevalence of gynecology cancers is expected to fuel the demand for gynecology drugs thereby, propelling the market growth.

However, the high cost and stringent regulatory framework that delays the approval of products are likely to impede market growth over the forecast period.

Gynecology Drugs Market Trends

This section covers the major market trends shaping the Gynecology Drugs Market according to our research experts:

Non-hormonal Therapy Segment is Expected to Witness High Growth Over the Forecast Period

Gynecology Drugs Industry Segmentation

Gynecological drug medications are used to treat ailments related to the female reproductive system. A major shift in the lifestyles of women led to a rise in the prevalence of gynecological disorders affecting the functioning of the uterus, ovaries, and appendages. The Gynecology Drugs Market is segmented by Therapeutics (Hormonal Therapy and Non-hormonal Therapy), by Indication (Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.